An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies
Latest Information Update: 07 Aug 2024
At a glance
- Drugs Ixazomib (Primary)
- Indications Amyloidosis; Lymphoma; Multiple myeloma
- Focus Adverse reactions
- Sponsors Takeda; Takeda Oncology
- 05 Aug 2024 Status changed from active, no longer recruiting to completed.
- 14 Jun 2024 Planned End Date changed from 31 Dec 2023 to 22 Feb 2027.
- 14 Jun 2024 Planned primary completion date changed from 31 Dec 2023 to 22 Feb 2027.